Vertex' charge continues with extended Orkambi approval

10 January 2018

One of the hottest biotech stocks in 2017 was Vertex Pharmaceuticals (Nasdaq: VRTX), a US biotech that specializes in cystic fibrosis (CF), with its value nearly doubling and the company reporting positive data from Phase I and II trials of triple combination regimens.

The good times look set to continue into 2018, if news announced on Wednesday is anything to go by.

The European Commission (EC) has granted an extension of the marketing authorization for Orkambi (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of CF in people with two copies of the F508del mutation, to include children ages 6 through 11.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK